Phenotypic and functional heterogeneity is one of the hallmarks of human cancers. Tumor
genotype variations among tumors within different patients are known as interpatient …

Tumor heterogeneity was traditionally considered in the genetic terms, but it has now been
broadened into many more facets. These facets represent a challenge in our understanding …

Cancer biology is profoundly influenced by changes in the epigenome. Because the
dynamic plasticity of the epigenome lends itself well to therapeutic manipulation, the past …

Cancer is a complex disease caused by genetic and epigenetic alterations in the control of
cell division. Findings from the field of cancer genomics and epigenomics have increased …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Cancer heterogeneity, long recognized as an important clinical determinant of patient
outcomes, was poorly understood at a molecular level. Genomic studies have significantly …

Defects in chromatin modifiers and remodelers have been described both for hematological
and solid malignancies, corroborating and strengthening the role of epigenetic aberrations …

The epigenome is a key determinant of transcriptional output. Perturbations within the
epigenome are thought to be a key feature of many, perhaps all cancers, and it is now clear …

Epigenetic and genetic alterations have long been thought of as two separate mechanisms
participating in carcinogenesis. A recent outcome of whole exome sequencing of thousands …

Cancer evolution at all stages is driven by both epigenetic abnormalities as well as genetic
alterations. Dysregulation of epigenetic control events may lead to abnormal patterns of …